enGene Holdings Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
ENGN Nasdaq 2834 www.engene.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for enGene Holdings Inc.

enGene to Participate in Upcoming Investor Conferences - Apr 29th, 2025 11:30 am
enGene Holdings Inc.'s (NASDAQ:ENGN) largest shareholders are private equity firms with 38% ownership, institutions own 35% - Apr 27th, 2025 12:13 pm
enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Apr 4th, 2025 12:00 pm
enGene to Present at the Stifel 2025 Virtual Targeted Oncology Forum - Apr 1st, 2025 12:00 pm
enGene Holdings Insider Ups Holding During Year - Mar 12th, 2025 11:29 am
enGene Reports First Quarter 2025 Financial Results and Provides Business Update - Mar 10th, 2025 8:05 pm
enGene to Participate in the Leerink Partners Global Healthcare Conference - Mar 4th, 2025 1:00 pm
enGene to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference - Feb 4th, 2025 1:00 pm
enGene to Present Three Posters at the 2025 ASCO Genitourinary Cancers Symposium (ASCO GU) Highlighting the Ongoing Clinical Development of Detalimogene Voraplasmid for the Treatment of Non-Muscle Invasive Bladder Cancer (NMIBC) - Jan 30th, 2025 1:00 pm
enGene Reports Full Year 2024 Financial Results and Provides a Business Update - Dec 19th, 2024 9:05 pm
With 52% ownership of the shares, enGene Holdings Inc. (NASDAQ:ENGN) is heavily dominated by institutional owners - Nov 17th, 2024 1:44 pm
enGene to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference - Nov 5th, 2024 1:00 pm
enGene Announces $60 Million Private Placement Financing - Oct 25th, 2024 12:00 pm
enGene Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - Oct 22nd, 2024 8:05 pm
enGene Appoints Joan Connolly as Chief Technology Officer and Anthony Cheung, Ph.D., as Chief Scientific Officer - Oct 21st, 2024 12:45 pm
Insider Buys Additional US$57k In enGene Holdings Stock - Oct 3rd, 2024 11:00 am
Detalimogene Demonstrates 71% Complete Response Rate at Any Time in Preliminary Analysis of LEGEND Pivotal Cohort - Sep 26th, 2024 10:30 am
enGene Reports Third Quarter 2024 Financial Results and Provides a Business Update - Sep 10th, 2024 8:33 pm
enGene Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - Jul 24th, 2024 8:05 pm
enGene Announces Appointment of Ron Cooper as Chief Executive Officer - Jul 24th, 2024 10:30 am